AstraZeneca Reports the US FDA Acceptance of sBLA and Granted Priority Review for Imfinzi (durvalumab) to Treat Patients with Extensive-Stage Small Cell Lung Cancer
Shots:
- The sBLA is based P-III CASPIAN study assessing Imfinzi + SOC (etoposide with either cisplatin or carboplatin)/ Imfinzi + tremelimumab + CT vs CT as monothx. in patients with previously untreated extensive-stage SCLC in 200+ centers across 23 countries
- The P-III CASPIAN study demonstrated improvement in OS (13.0 cs 10.3 mos.) with a reduction in risk of death by 27%- @18mos. alive patients (33.9% vs 24.7%). The PDUFA is set for Q1’20
- Imfinzi is a mAb targeting PD-L1- blocking the interaction of PD-L1 with PD-1 and CD80- approved in 54 countries for stage III NSCLC following chemoradiation therapy
Click here to read full press release/ article
Ref: PRNewswire | Image: AstraZeneca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com